Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: COMTAN

« Back to Dashboard
Comtan is a drug marketed by Orion Pharma and is included in one NDA. It is available from ten suppliers. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in thirty-seven countries.

The generic ingredient in COMTAN is entacapone. There are nineteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the entacapone profile page.

Summary for Tradename: COMTAN

Suppliers / Packagers: see list17

Pharmacology for Tradename: COMTAN

Clinical Trials for: COMTAN

Augmenting Effects of L-DOPS With Carbidopa and Entacapone
Status: Terminated Condition: Parkinson Disease; Multiple System Atrophy; Autonomic Nervous System Diseases

Effect of Entacapone on Bodyweight Loss in Obese Population
Status: Recruiting Condition: Obesity

COMT Polymorphism and Entacapone Efficacy
Status: Completed Condition: Parkinson's Disease

Pilot Study of Entacapone for Methamphetamine Abuse
Status: Recruiting Condition: Methamphetamine Dependence

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
Status: Completed Condition: Parkinson's Disease

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
Status: Terminated Condition: Parkinson's Disease

Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off
Status: Completed Condition: Parkinson's Disease

Entacapone Augmentation for Schizophrenia
Status: Completed Condition: Schizophrenia

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Status: Completed Condition: Parkinson's Disease

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
Status: Completed Condition: Parkinson's Disease With End of Dose "Wearing Off"

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma
TABLET;ORAL020796-001Oct 19, 1999RXYes6,599,530<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: COMTAN

Drugname Dosage Strength RLD Submissiondate
entacaponeTablets200 mgComtan4/11/2007

International Patent Family for Tradename: COMTAN

Country Document Number Publication Date
Hungary0103454Jan 28, 2002
Bulgaria105436Nov 30, 2001
Indonesia29026Jul 26, 2001
Denmark1112065Apr 05, 2004
Germany69913714Jan 29, 2004
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn